These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29520138)

  • 1. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide.
    Zhang L; Ren Y; Wang Y; He Y; Feng W; Song C
    Int J Nanomedicine; 2018; 13():1097-1105. PubMed ID: 29520138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
    He Y; Zhang L; Song C
    Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy.
    He Y; Zhang L; Zhu D; Song C
    Int J Nanomedicine; 2014; 9():4055-66. PubMed ID: 25187709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
    Schwendener RA; Fiebig HH; Berger MR; Berger DP
    Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.
    Ahmad A; Wang YF; Ahmad I
    Methods Enzymol; 2005; 391():176-85. PubMed ID: 15721381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer.
    Rentsch KM; Schwendener RA; Pestalozzi BC; Sauter C; Wunderli-Allenspach H; Hänseler E
    Eur J Clin Pharmacol; 1998 Mar; 54(1):83-9. PubMed ID: 9591936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrone-targeted liposomes for mitoxantrone delivery via estrogen receptor: In vivo targeting efficacy, antitumor activity, acute toxicity and pharmacokinetics.
    Xu G; Tang H; Chen J; Zhu M; Xie Y; Li Y; Hao Q; Sun Y; Cong D; Meng Q; Ren Z; Li Q; Bao H; Lv Z; Li Y; Pei J
    Eur J Pharm Sci; 2021 Jun; 161():105780. PubMed ID: 33667664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.
    Orthmann A; Zeisig R; Süss R; Lorenz D; Lemm M; Fichtner I
    Pharm Res; 2012 Jul; 29(7):1949-59. PubMed ID: 22399388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LHD-Modified Mechanism-Based Liposome Coencapsulation of Mitoxantrone and Prednisolone Using Novel Lipid Bilayer Fusion for Tissue-Specific Colocalization and Synergistic Antitumor Effects.
    Hu T; Cao H; Yang C; Zhang L; Jiang X; Gao X; Yang F; He G; Song X; Tong A; Guo G; Gong C; Li R; Zhang X; Wang X; Zheng Y
    ACS Appl Mater Interfaces; 2016 Mar; 8(10):6586-601. PubMed ID: 26907854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone- and Folate-TPGS2k Conjugate Hybrid Micellar Aggregates To Circumvent Toxicity and Enhance Efficiency for Breast Cancer Therapy.
    Guissi NE; Li H; Xu Y; Semcheddine F; Chen M; Su Z; Ping Q
    Mol Pharm; 2017 Apr; 14(4):1082-1094. PubMed ID: 28191959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.
    Pedrosa LR; Ten Hagen TL; Süss R; van Hell A; Eggermont AM; Verheij M; Koning GA
    Pharm Res; 2015 Apr; 32(4):1354-67. PubMed ID: 25319103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
    Rentsch KM; Horber DH; Schwendener RA; Wunderli-Allenspach H; Hänseler E
    Br J Cancer; 1997; 75(7):986-92. PubMed ID: 9083333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.
    Lu B; Xiong SB; Yang H; Yin XD; Zhao RB
    Int J Pharm; 2006 Jan; 307(2):175-81. PubMed ID: 16314056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of luteinizing hormone-releasing hormone-ferrosoferric oxide nanoparticles in targeted imaging of breast tumors.
    Nian D; Shi P; Sun J; Ren L; Hao X; Han J
    J Int Med Res; 2019 Apr; 47(4):1749-1757. PubMed ID: 30880516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux.
    Ling G; Zhang T; Zhang P; Sun J; He Z
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1351-9. PubMed ID: 26754913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
    Lu B; Xiong SB; Yang H; Yin XD; Chao RB
    Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic effect and toxicity of compound vincristine liposome on breast cancer in nude mice].
    Chen T; Hou S; Wang Y; Zhang W; Liao H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):127-9, 143. PubMed ID: 19334570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.